lifesciencesipreview8m
'This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article ...
K-12 Genome Editing at Only $2 a Pop
CRISPRkit aims to make "gene editing accessible for everyone, everywhere." Aimed at K-12 students and people of any age ...
bluebird bio: Scientific Success And Financial Success, And The Gap Between
Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...
STAT1d
Gene therapy for sickle cell disease remains a tough business model — and may never work
Gene therapy for sickle cell disease remains a tough business model — and may never work, @adamfeuerstein writes.
Health Canada Oks Vertex's CASGEVY, First CRISPR/Cas9 Gene-Edited Therapy For Sickle Cell Disease
Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...
Yale Daily News1d
New Yale Medical Center advances rare disease diagnosing
“The sickle cell cure was the first ever FDA-approved therapy involving CRISPR-Cas9 genome editing, and I look forward to ...
MIT Technology Review1d
The Download: a CRISPR patent battle, and the promise of tiny AI
Two Nobel Prize winners want to cancel their own CRISPR patents in Europe In the decade-long fight to control CRISPR, the ...
Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
Despite a 65% stock drop since 2022, Intellia's advancements in Phase 3 trials and strong partnerships make NTLA stock a ...
News Medical1d
CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies
In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...
MIT Technology Review1d
Two Nobel Prize winners want to cancel their own CRISPR patents in Europe
But now, in a surprise twist, the team that earned the Nobel Prize in chemistry for developing CRISPR is asking to cancel two ...
CRISPR-Cas13: A new frontier in RNA-editing with therapeutic potential
In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1 ...